Title (en)

RECOMBINANT VSV FOR THE TREATMENT OF TUMOR CELLS

Title (de)

REKOMBINANTE VSV ZUR BEHANDLUNG VON TUMORZELLEN

Title (fr)

VSV RECOMBINANT POUR LE TRAITEMENT DE CELLULES TUMORALES

Publication

EP 1411880 B1 20180425 (EN)

Application

EP 02749985 A 20020711

Priority

- US 0222146 W 20020711
- US 30412501 P 20010711

Abstract (en)

[origin: WO03005964A2] The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual.

IPC 8 full level

A61K 38/45 (2006.01); **C12N 15/09** (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 38/20** (2006.01); **A61K 38/21** (2006.01); **A61K 48/00** (2006.01); **A61P 1/02** (2006.01); **A61P 13/08** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 35/04** (2006.01); **C07K 14/54** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 5/22** (2006.01); **C12N 7/00** (2006.01); **C12N 7/01** (2006.01); **C12N 15/20** (2006.01); **C12N 15/24** (2006.01); **C12N 15/47** (2006.01); **C12N 15/57** (2006.01); **C12N 15/86** (2006.01)

CPC (source: EP US)

A61K 35/766 (2013.01 - US); **A61K 38/2026** (2013.01 - EP US); **A61K 38/208** (2013.01 - EP US); **A61K 38/215** (2013.01 - EP US); **A61K 38/217** (2013.01 - EP US); **A61K 38/45** (2013.01 - EP US); **A61K 48/0058** (2013.01 - US); **A61P 1/02** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **C07K 14/5406** (2013.01 - EP US); **C12N 15/86** (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); C12N 2760/20232 (2013.01 - US); C12N 2760/20243 (2013.01 - EP US)

Citation (examination)

BRADLEY D HOWARD ET AL: "Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir", CANCER GENE THERAPY, vol. 7, no. 6, 1 January 2000 (2000-01-01), pages 927 - 938, XP055259784, DOI: 10.1038/sj.cgt.7700180

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03005964 A2 20030123; **WO 03005964 A3 20030424**; CA 2452517 A1 20030123; EP 1411880 A2 20040428; EP 1411880 A4 20050720; EP 1411880 B1 20180425; JP 2004537305 A 20041216; US 2003044386 A1 20030306; US 2010113567 A1 20100506; US 2013210135 A1 20130815; US 2016022748 A1 20160128

DOCDB simple family (application)

US 0222146 W 20020711; CA 2452517 A 20020711; EP 02749985 A 20020711; JP 2003511773 A 20020711; US 17589808 A 20080718; US 19459402 A 20020711; US 201213724393 A 20121221; US 201514812454 A 20150729